Aquablation for benign prostatic hyperplasia: real‐world prostate size relevance and bleeding events across 6 years
BJU International · 2026
DOI: 10.1111/bju.70118 ↗Kurz gefasst
Fachartikel in der Zeitschrift BJU International, 2026. Verfasst von Mario Bitar und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Urology, Department of Surgery, University of Toronto, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Prostatic Hyperplasia, Postoperative Hemorrhage, Ablation Techniques, Prostate. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objective
To present large‐scale safety outcomes, with a particular focus on postoperative bleeding following Aquablation for benign prostatic hyperplasia. Patients and Methods Patients who underwent Aquablation between 2019 and 2024 across Asia, Europe, and North America were assessed to evaluate trends in treated prostate sizes, which were visualised using density plots. A corporate prospective database was maintained, incorporating case recordings and data collected by on‐site company representatives. In addition, the incidence of postoperative bleeding—defined as transfusion or surgical takeback for haemostatic fulguration—was analysed using data from the United States Food and Drug Administration (FDA) Manufacturer and User Facility Device Experience (MAUDE) database and procedure counts by the manufacturer.
Results
A total of 70 270 Aquablation procedures were evaluated over the period from 2019 to 2024. The mean (standard deviation) prostate volume was 87.3 (42.4) mL, with a maximum recorded size of 1189 mL. Density plot analysis of prostate volumes demonstrated consistent utilisation of Aquablation across the full range of prostate sizes throughout all years studied. The overall rate of blood transfusion or return to the operating room for haemostatic fulguration was 0.2%, indicating a favourable safety profile across a very wide range of prostate sizes.
Conclusions
Aquablation has been consistently utilised across a broad spectrum of prostate sizes, with a low overall rate of transfusion or return to the operating room for bleeding control. These findings highlight the procedure's broad applicability and favourable safety profile in real‐world practice from 2019 to 2024.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Urology, Department of Surgery, University of Toronto, Toronto, Ontario, Canada.
- Division of Urology, Centre Hospitalier de l'Université de Montréal (CHUM), Montréal, Quebec, Canada.
- Smith Institute of Urology, Northwell Health, Plainview Hospital, Syosset, NY, USA.
- BPH Canada, Prostate Surgical Institute, Montreal, Quebec, Canada.
ORCID-Profile: Mario Bitar, Roseanne Ferreira, Naeem Bhojani, Dean Elterman
Zitieren
APA
Bitar, M., Ferreira, R., Shprits, S., Buksh, O., Bhojani, N., Chughtai, B., Zorn, K. C., & Elterman, D. (2026). Aquablation for benign prostatic hyperplasia: real‐world prostate size relevance and bleeding events across 6 years. BJU International. https://doi.org/10.1111/bju.70118
Vancouver
Bitar M, Ferreira R, Shprits S, Buksh O, Bhojani N, Chughtai B, et al. Aquablation for benign prostatic hyperplasia: real‐world prostate size relevance and bleeding events across 6 years. BJU International. 2026. doi:10.1111/bju.70118
BibTeX
@article{Bitar2026,
author = {Bitar, Mario and Ferreira, Roseanne and Shprits, Sagi and Buksh, Omar and Bhojani, Naeem and Chughtai, Bilal and Zorn, Kevin C and Elterman, Dean},
title = {Aquablation for benign prostatic hyperplasia: real‐world prostate size relevance and bleeding events across 6 years},
journal = {BJU International},
year = {2026},
doi = {10.1111/bju.70118}
}
EUVIMED